(Q37843836)

English

Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers

scientific article published on 17 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Shouji Shimoyama

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

17 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

729-739

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-011-1583-2

0 references

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Rho family proteins: coordinating cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Ras and Rho regulation of the cell cycle and oncogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

What tangled webs they weave: Rho-GTPase control of angiogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Vascular endothelial growth factor in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Anti-angiogenic therapy against gastrointestinal tract cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Targeted HER2 treatment in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Activation of Raf as a result of recruitment to the plasma membrane

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Protein lipidation in cell signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase for ras p21S.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Rho GTPases are over-expressed in human tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

RhoC is essential for the metastasis of gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Potential Anticancer Effects of Statins: Fact or Fiction?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Statins and cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1583-2

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE00766

Identifiers

10.1007/S00280-011-1583-2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37843836&oldid=1730560949"